The more we know about our visitors, the easier it will be for us to publish everything you want to see.

Keep me logged in Forgot your password?

Please wait...

Please wait...

Electronic Health Records

Electronic Health Records

Oncologists who make the switch from paper to electronic health records (EHR) now are eligible for cash incentives from the Center for Medicare and Medicaid Services (CMS).
Oral Mucositis in Cancer Patients

Oral Mucositis in Cancer Patients

Oral mucositis is a common side effect of most chemotherapeutic drugs, and radiotherapy of the oral, and head and neck cancers.
Managing Treatment-Related Side Effects

Managing Treatment-Related Side Effects

Approximately one-third of cancer patients undergoing therapy and over three-fourths of those with advanced disease experience some degree of pain.
New Treatments for Advanced Melanoma

New Treatments for Advanced Melanoma

The introduction of ipilimumab and vemurafenib may be the beginning of the identification of melanoma treatment options that improve survival outcomes based upon patient immune response.
Emerging Therapies for Ovarian Cancer

Emerging Therapies for Ovarian Cancer

Ovarian cancer accounts for about 3% of cancers among women, but causes more deaths than any other cancer of the female reproductive system.
Cancer Medicine and Liability

Cancer Medicine and Liability

What are the best ways to combine good medical practice with good medico‑legal and legal practice for 21st century cancer medicine?
Breast Cancer and Memory Loss

Breast Cancer and Memory Loss

Many women experience chemotherapy-induced cognitive changes in memory, attention, psychomotor speed, and executive functioning.
Expanded Treatments for Multiple Myeloma

Expanded Treatments for Multiple Myeloma

Treatment-refractoriness and disease relapse have necessitated continuous development of novel therapeutic agents and repurposing of current standard therapies.

From The Advisory Board
Case Study: Castrate-Resistant Prostate Cancer
Neal D. Shore, MD, FACS, an internationally renowned expert in the treatment of metastatic castrate-resistant prostate cancer (MCRPC), shares a
case study that analyzes the current data and guidelines regarding second-line hormonal therapy and the scanning pathway in the MCRPC patient.

Latest News

 
 
 
 
 
 
 
 
 
 
 
 

The Advisor Blog

 

News from Oncology Nurse Advisor

Minimally invasive esophagectomy reduces morbidity

"Ex vivo" surgery works for abdominal tumors

Cancer pain often undertreated, especially among minorities

More chemotherapy might be best move for some children with leukemia

Review supports aspirin for cancer prevention

Editorial Advisory Board

Barbara Ann Burtness, M.D

Steven Cohen, MD

E. David Crawford, MD

Jeffrey M. Farma, MD

Sergio A. Giralt, MD

Todd Morgan, MD

Tara Morrison, MD, FRCPC

Edith A. Perez, MD

Neal D. Shore, M.D., FACS

Mark A. Socinski, MD

Click the cancer type below for a full listing of treatment regimens
Bone Cancer
Brain Cancer
Breast Cancer
Endocrine Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Head and Neck Cancer
Hematologic Cancers
Lung Cancer
Other Cancers
Rare Cancers
Skin Cancer

MPR Drug News

Pertzye Approved for Treating Pancreatic Insufficiency

BioThrax Administration Schedule Changed

Omeclamox-Pak Available for Treating H. pylori

 Subscribe to the RSS for this page  [view all our RSS feeds here]

© 2012 Haymarket Media, Inc.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions